[go: up one dir, main page]

NO20025154D0 - Imidazopyrimidinderivater og triazolpyrimidinderivater - Google Patents

Imidazopyrimidinderivater og triazolpyrimidinderivater

Info

Publication number
NO20025154D0
NO20025154D0 NO20025154A NO20025154A NO20025154D0 NO 20025154 D0 NO20025154 D0 NO 20025154D0 NO 20025154 A NO20025154 A NO 20025154A NO 20025154 A NO20025154 A NO 20025154A NO 20025154 D0 NO20025154 D0 NO 20025154D0
Authority
NO
Norway
Prior art keywords
sup
sub
derivatives
optionally substituted
imidazopyrimidine
Prior art date
Application number
NO20025154A
Other languages
English (en)
Norwegian (no)
Other versions
NO20025154L (no
Inventor
Takeshi Yura
Arnel B Concepcion
Gyoonhee Han
Makiko Marumo
Hiroko Katsumata
Norihiro Kawamura
Toshio Kokubo
Hiroshi Komura
Yingfu Li
Timothy Bruno Lowinger
Muneto Mogi
Noriyuki Yamamoto
Nagahiro Yoshida
Scott C Miller
Margaret A Popp
Niko M Redmann
Martha E Rodriguez
William J Scott
Ming Wang
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO20025154D0 publication Critical patent/NO20025154D0/no
Publication of NO20025154L publication Critical patent/NO20025154L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20025154A 2000-04-28 2002-10-25 Imidazopyrimidinderivater og triazolpyrimidinderivater NO20025154L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000128870A JP2001302667A (ja) 2000-04-28 2000-04-28 イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
PCT/EP2001/004357 WO2001083485A1 (en) 2000-04-28 2001-04-17 Imidazopyrimidine derivatives and triazolopyrimidine derivatives

Publications (2)

Publication Number Publication Date
NO20025154D0 true NO20025154D0 (no) 2002-10-25
NO20025154L NO20025154L (no) 2002-10-25

Family

ID=18638240

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025154A NO20025154L (no) 2000-04-28 2002-10-25 Imidazopyrimidinderivater og triazolpyrimidinderivater

Country Status (37)

Country Link
US (1) US6911443B2 (es)
EP (1) EP1278750B1 (es)
JP (2) JP2001302667A (es)
KR (1) KR20030009456A (es)
CN (1) CN1263756C (es)
AR (1) AR033367A1 (es)
AT (1) ATE272639T1 (es)
AU (1) AU783043B2 (es)
BG (1) BG107166A (es)
BR (1) BR0110404A (es)
CA (1) CA2407531A1 (es)
CZ (1) CZ20023551A3 (es)
DE (1) DE60104671T2 (es)
DK (1) DK1278750T3 (es)
DO (1) DOP2001000151A (es)
EE (1) EE200200606A (es)
ES (1) ES2225546T3 (es)
HR (1) HRP20020943A2 (es)
HU (1) HUP0300846A2 (es)
IL (1) IL151919A0 (es)
MA (1) MA25746A1 (es)
MX (1) MXPA02010579A (es)
MY (1) MY141578A (es)
NO (1) NO20025154L (es)
NZ (2) NZ526221A (es)
PE (1) PE20011287A1 (es)
PL (1) PL358106A1 (es)
PT (1) PT1278750E (es)
RU (1) RU2306313C2 (es)
SI (1) SI1278750T1 (es)
SK (1) SK15332002A3 (es)
SV (1) SV2001000416A (es)
TR (1) TR200402300T4 (es)
TW (1) TWI222974B (es)
UA (1) UA72615C2 (es)
WO (1) WO2001083485A1 (es)
ZA (1) ZA200207676B (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1385823T3 (da) 2001-04-09 2007-03-26 Novartis Vaccines & Diagnostic Guanidinoforbindelser som melanocortin-4-receptor- (MC4-R) -agonister
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
EP1674454A4 (en) * 2003-10-17 2006-12-27 Nippon Kayaku Kk SUBSTITUTED 2-AMINO-1,2,4-TRIAZOLO 1,5-A-PYRIMIDINE DERIVATIVE AND THE USE THEREOF
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
DK1718649T3 (da) 2004-01-31 2009-08-24 Actimis Pharmaceuticals Inc Imidazo[1,2-c]pyrimidinyleddikesyrederivater
US20050288502A1 (en) * 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2577846A1 (en) 2004-08-23 2006-03-02 Wyeth Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
JP2008510815A (ja) 2004-08-23 2008-04-10 ワイス 血栓症および心臓血管疾患の治療にて有用な調節剤であるプラスミノゲン活性化因子阻害剤1型(pai−1)としてのオキサゾロ−ナフチル酸
AU2005277137A1 (en) 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as PAI-1 inhibitors
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1854793A4 (en) 2005-02-28 2011-01-26 Japan Tobacco Inc NEW AMINOPYRIDEIN COMPOUND WITH SYK-HEMDERING EFFECT
US7442700B2 (en) 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007042298A1 (en) * 2005-10-13 2007-04-19 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
SI3034075T1 (sl) * 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
CA2673965A1 (en) 2006-12-28 2008-07-10 Taisho Pharmaceutical Co., Ltd. Pyrazolopyrimidine compound
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
DK2205569T3 (da) 2007-09-25 2012-05-21 Actimis Pharmaceuticals Inc Alkylthiopyrimidiner som crth2-antagonister
RU2491279C2 (ru) 2007-09-25 2013-08-27 Актимис Фармасьютикалз, Инк. 2-s-бензилзамещенные пиримидины в качестве антагонистов crth2
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
ES2590804T3 (es) 2008-12-08 2016-11-23 Gilead Connecticut, Inc. Inhibidores de Imidazopyrazine Syk
WO2010068258A1 (en) 2008-12-08 2010-06-17 Cgi Pharmaceuticals, Inc. Imidazopyrazine syk inhibitors
WO2010147898A2 (en) * 2009-06-15 2010-12-23 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
SI2516434T1 (sl) 2009-12-23 2015-10-30 Takeda Pharmaceutical Company Limited Zliti heteroaromatski pirolidinoni kot inhibitorji SYK
KR101717809B1 (ko) * 2010-03-11 2017-03-17 질레드 코네티컷 인코포레이티드 이미다조피리딘 syk 억제제
EP2558468B1 (en) * 2010-04-14 2015-04-01 Array Biopharma, Inc. 5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases
WO2012154520A1 (en) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
KR20140028062A (ko) 2011-05-10 2014-03-07 머크 샤프 앤드 돔 코포레이션 Syk 억제제로서의 아미노피리미딘
WO2012154518A1 (en) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
JP6026525B2 (ja) 2011-06-22 2016-11-16 武田薬品工業株式会社 置換6−アザ−イソインドリン−1−オン誘導体
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
EP2763975B1 (en) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
US9006444B2 (en) 2011-10-05 2015-04-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
EP2763976B1 (en) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
JP2014528475A (ja) * 2011-10-12 2014-10-27 アレイ バイオファーマ、インコーポレイテッド 5,7置換イミダゾ[1,2−c]ピリミジン
EP2799431B1 (en) * 2011-12-28 2018-01-24 FUJIFILM Corporation Novel nicotinamide derivative or salt thereof
US9242984B2 (en) 2012-06-20 2016-01-26 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as Syk inhibitors
WO2013192128A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
WO2013192098A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2863915B1 (en) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2884982B1 (en) 2012-08-20 2017-09-20 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2900665B1 (en) 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
US9624210B2 (en) 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
WO2014100314A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
US9499534B2 (en) 2013-04-26 2016-11-22 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
WO2014176210A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3027618B1 (en) 2013-07-30 2020-07-08 Gilead Connecticut, Inc. Polymorph of syk inhibitors
US9918939B2 (en) 2013-07-30 2018-03-20 Gilead Connecticut, Inc. Formulation of Syk inhibitors
AU2014360537B2 (en) 2013-12-04 2017-09-07 Gilead Sciences, Inc. Methods for treating cancers
EP3083559B1 (en) 2013-12-20 2021-03-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9670196B2 (en) 2013-12-20 2017-06-06 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
WO2015138273A1 (en) 2014-03-13 2015-09-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
MY185837A (en) * 2014-03-19 2021-06-12 Boehringer Ingelheim Int Heteroaryl syk inhibitors
JP6310144B2 (ja) 2014-07-14 2018-04-18 ギリアード サイエンシーズ, インコーポレイテッド がんを処置するための組み合わせ
AU2016320297B2 (en) 2015-09-11 2020-08-27 Boehringer Ingelheim International Gmbh Pyrazolyl-substituted heteroaryls and their use as medicaments
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
MX2020004155A (es) 2017-10-19 2020-08-03 Bayer Animal Health Gmbh Uso de pirrolidonas heteroaromaticas fusionadas para el tratamiento y prevencion de enfermedades en animales.
KR102740831B1 (ko) 2017-11-14 2024-12-11 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도
KR102775718B1 (ko) 2017-11-14 2025-03-06 칠드런'즈 메디컬 센터 코포레이션 인간 면역 반응을 조정하기 위한 이미다조피리미딘의 용도
US20210113540A1 (en) * 2018-06-06 2021-04-22 National University Corporation Hokkaido University Treatment agent and pharmaceutical composition for glioma
WO2019235572A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 固形がんの処置剤および医薬組成物
WO2019235571A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 血液がんの処置剤および医薬組成物
SG11202103839UA (en) 2018-10-31 2021-05-28 Gilead Sciences Inc Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer
UY39517A (es) * 2020-11-13 2022-06-30 Biogen Ma Inc Inhibidores de la btk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483987A (en) * 1983-06-20 1984-11-20 G. D. Searle & Co. 8-Substituted 7-phenyl-1,2,4-triazolo[2,3-c]pyrimidines-5-amines and amides
FR2549834B1 (fr) * 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
DE69839735D1 (de) * 1997-12-15 2008-08-28 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
US6673564B2 (en) * 1999-10-18 2004-01-06 Millennium Pharmaceuticals, Inc. Methods for using 22045, a human cyclic nucleotide phosphodiesterase

Also Published As

Publication number Publication date
SK15332002A3 (sk) 2003-06-03
PT1278750E (pt) 2004-11-30
MA25746A1 (fr) 2003-04-01
MXPA02010579A (es) 2003-05-14
JP2001302667A (ja) 2001-10-31
PL358106A1 (en) 2004-08-09
SI1278750T1 (en) 2005-02-28
TWI222974B (en) 2004-11-01
AU783043B2 (en) 2005-09-22
AU6220401A (en) 2001-11-12
DOP2001000151A (es) 2002-05-15
IL151919A0 (en) 2003-04-10
ZA200207676B (en) 2003-09-25
HRP20020943A2 (en) 2005-02-28
BG107166A (bg) 2003-06-30
UA72615C2 (en) 2005-03-15
DE60104671D1 (de) 2004-09-09
ES2225546T3 (es) 2005-03-16
US20040054179A1 (en) 2004-03-18
CA2407531A1 (en) 2001-10-25
PE20011287A1 (es) 2002-02-27
CN1263756C (zh) 2006-07-12
CZ20023551A3 (cs) 2003-01-15
HUP0300846A2 (hu) 2003-08-28
DE60104671T2 (de) 2005-12-29
WO2001083485A1 (en) 2001-11-08
DK1278750T3 (da) 2004-11-22
EP1278750A1 (en) 2003-01-29
EP1278750B1 (en) 2004-08-04
HK1058362A1 (en) 2004-05-14
NZ522241A (en) 2004-04-30
US6911443B2 (en) 2005-06-28
BR0110404A (pt) 2003-02-11
EE200200606A (et) 2004-04-15
NZ526221A (en) 2005-01-28
NO20025154L (no) 2002-10-25
SV2001000416A (es) 2001-07-03
ATE272639T1 (de) 2004-08-15
JP2003535067A (ja) 2003-11-25
MY141578A (en) 2010-05-14
AR033367A1 (es) 2003-12-17
RU2306313C2 (ru) 2007-09-20
KR20030009456A (ko) 2003-01-29
TR200402300T4 (tr) 2004-12-21
CN1439009A (zh) 2003-08-27

Similar Documents

Publication Publication Date Title
NO20025154D0 (no) Imidazopyrimidinderivater og triazolpyrimidinderivater
FI970317A0 (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
EA200000334A1 (ru) Производные карбоксамидотиазолов, их получение, содержащие их фармацевтические композиции
GC0000221A (en) Pyrimidinone compounds, processes for their preparation, intermediates useful in their preparation, and pharmaceutical compositions containing them
NO2015020I2 (no) Ceritinib eller et farmasøytisk akseptabelt salt derav
BR9710780A (pt) Novos compostos de para-terefenila
DK633088D0 (da) Hidtil ukendte forbindelser
NO911121D0 (no) Fremgangsmaate for fremstilling av nye skvalen-synetase-inhibitorer.
PE20020524A1 (es) 7-oxo-piridopirimidinas como inhibidores de quinasas
DK173783D0 (da) Fremgangsmade til fremstilling af imidazo (1,2-alfa)pyridiner
DE60001182D1 (de) Erythromycin-Derivate, ihr Verfahren zur Herstellung und ihre Verwendung als Arzneimittel
FI812183L (fi) 3,1-benzoxazin-2-oner deras framstaellning och anvaendning
NO20002490L (no) FremgangsmÕte for fremstilling av 1,4-dihydropyridiner og forbindelser anvendt ved denne fremgangsmÕten
AU561679B2 (en) 5-alkyl-1,6-naphtyridin-2(1h)-ones
NO960441L (no) Benzopyraner og farmasöytiske forbindelser inneholdende dem
HUT41739A (en) Herbicidal and plant growth regulating compositions comprising novel "1-aryl-5-alkoxy-imino-alkyl-aminopyrazoles as active substance and process for preparing the novel active substances
EP1216988A4 (en) THIOALKYLAMINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
HUT42277A (en) Herbicides containing as active subtance derivatives of new 1-aryl-4-nitro-pirasole and process for production of the active substances
HUT44012A (en) Herbicide compositions containing new aryl-tetrahydro-phtalimide derivatives and process for producing the active components
IT1313702B1 (it) Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piperidine.
DK0627429T3 (da) Loracarbefisopropanolat og fremgangsmåde til omdannelse af loracarbefisopropanolat til loracarbefmonohydrat
HUT36469A (en) Process for producing 2-/n-pyrrolidino/-3-isobuthyloxy-n-/substituted phenyl/-n-benzyl-propyl-amines and acid additional salts thereof
DK0786459T3 (da) Fremgangsmåde til fremstilling af en heterobicyklisk alkoholenantiomer
DK1250335T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af imidazopyridiner
DE60335960D1 (de) 1,2,4-triazolderivat, verfahren zu dessenherstellung, und dieses enthaltende pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application